EBMT 2021 | Novel agents for CMV treatment in allo-HSCT recipients

Name: Novel agents for CMV treatment in allo-HSCT recipients
Uploaded: 2021-03-08T00:00:00Z
Duration: 2 min 30 s

Roy Chemaly • 8 Mar 2021

EBMT 2021

General Letermovir Maribavir

Roy F Chemaly, MD, MPH, FIDSA, FACP, MD Anderson Cancer Center, Houston, TX, gives an outline of new agents and new tools for the management of cytomegalovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dr Chemaly discusses the use of letermovir for the treatment of patients with positive CMV serostatus receiving allo-HSCT to prevent CMV reactivation, as well as highlighting its efficacy against resistant and refractory CMV infection. Dr Chemaly also outlines the potential approval of maribavir for the treatment of refractory and resistant CMV infection for patients receiving allo-HSCT. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Dr Roy F Chemaly, MD, MPH, FIDSA, FACP, has received research Grants from Gilead, Pulmotec, Janssen, Karius, Chimerix, Merck, Viracor, Takeda/Shire, and Ansun Pharmaceuticals; and has participated in advisory boards or consultancy work for ADMA Biologics, Pulmotec, Ablynx, Janssen, Merck, Takeda, ReViral, Kyorin, Chimerix, Partner Therapeutics, and Ansun Pharmaceuticals.